- Home
- WHF vs LENZ Comparison
WHF vs LENZ Comparison
Compare WHF & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | LENZ |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | 152 |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 106.8M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WHF | LENZ |
|---|---|---|
| Price | $7.37 | $3.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.83 | ★ $24.00 |
| AVG Volume (30 Days) | 105.8K | ★ 719.7K |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | ★ 14.26% | N/A |
| EPS Growth | ★ 31.91 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $19,088,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.38 | $153.04 |
| P/E Ratio | $16.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.07 | $3.35 |
| 52 Week High | $7.84 | $42.98 |
Technical Indicators
Market Signals| Indicator | WHF | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 33.51 |
| Support Level | $6.85 | N/A |
| Resistance Level | $7.58 | $6.11 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 76.00 | 23.85 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.